TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
Brief Summary: This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a combination therapy of fluticasone and salmeterol (a long-acting beta-agonist). Fluticasone, montelukast, and the combination therapy of fluticasone and salmeterol (Advair Diskus®) are all approved for the treatment of asthma. We are looking at whether the three treatments are equally effective for reducing the number and the severity of asthma attacks in subjects with mild to moderately severe asthma.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Montelukast Placebo | Intervention Type: DRUG; Name: Montelukast Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Salmeterol, Montelukast; Assigned to Arm(s): 1
B: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Singular pill; Type: EXPERIMENTAL; Interventions: Drug: singular | Intervention Type: DRUG; Name: singular; Assigned to Arm(s): Singular pill | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo pill
C: Arm Label: Xolair; Type: EXPERIMENTAL; Interventions: Drug: omalizumab (Xolair), Drug: corticosteroids, Drug: long-acting beta-agonists | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: corticosteroids, Drug: long-acting beta-agonists | Intervention Type: DRUG; Name: omalizumab (Xolair); Assigned to Arm(s): Xolair | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): Xolair, placebo | Intervention Type: DRUG; Name: long-acting beta-agonists; Assigned to Arm(s): Xolair, placebo
D: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
Brief Summary: This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a combination therapy of fluticasone and salmeterol (a long-acting beta-agonist). Fluticasone, montelukast, and the combination therapy of fluticasone and salmeterol (Advair Diskus®) are all approved for the treatment of asthma. We are looking at whether the three treatments are equally effective for reducing the number and the severity of asthma attacks in subjects with mild to moderately severe asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
C: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: X: Zinc sulphate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc sulphate | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc sulphate; Assigned to Arm(s): X: Zinc sulphate
C: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and vitamin A single dose at enrollment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo and vitamin A single dose at enrollment | Intervention Type: DRUG; Name: Zinc and vitamin A single dose at enrollment; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo and vitamin A single dose at enrollment; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Zinc sulphate; Assigned to Arm(s): N/A
D: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
B: Arm Label: Early postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (<3-day postpartum) | Arm Label: Late postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (6 wk postpartum) | Arm Label: Early & late postpartum vitamin A suppl; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (<3-day and 6 wk postpartum) | Arm Label: No postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (<3-day postpartum); Assigned to Arm(s): Early postpartum vitamin A suppl. | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (6 wk postpartum); Assigned to Arm(s): Late postpartum vitamin A suppl. | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (<3-day and 6 wk postpartum); Assigned to Arm(s): Early & late postpartum vitamin A suppl | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): No postpartum vitamin A suppl.
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and vitamin A single dose at enrollment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo and vitamin A single dose at enrollment | Intervention Type: DRUG; Name: Zinc and vitamin A single dose at enrollment; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo and vitamin A single dose at enrollment; Assigned to Arm(s): 2
B: Arm Label: Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Zinc syrup; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Liquid zinc syrup | Arm Label: Zinc tablet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Liquid placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Liquid zinc syrup; Assigned to Arm(s): Zinc syrup | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc tablet; Assigned to Arm(s): Zinc tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Liquid placebo supplement; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa
Brief Summary: The purpose of the study is to see if giving vitamin and mineral supplements helps to protect infants and children from diarrhea, which vitamins and minerals help to improve a child's weight and growth, and if the same results occur in infants and children with HIV. HIV is the virus that causes AIDS. Study participants will include 516 infants aged 4-6 months. Participants will include: (1) HIV-infected children, (2) HIV-uninfected children with HIV-infected mothers, and (3) HIV-uninfected children with HIV-uninfected mothers. Subjects will have an equal chance of receiving one of three different vitamin and/or mineral supplements during the study. Study procedures will include up to 7 blood samples and stool samples every 3 months and body composition every 6 months. Participants will be involved in the study for up to 18 months.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Zinc sulphate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc sulfate as dietary supplementation | Arm Label: Zinc Amino Acid Chelate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc amino acid chelate as dietary supplementation | Arm Label: Milk without fortification; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk without fortification without zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc sulfate as dietary supplementation; Assigned to Arm(s): Zinc sulphate | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc amino acid chelate as dietary supplementation; Assigned to Arm(s): Zinc Amino Acid Chelate | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk without fortification without zinc; Assigned to Arm(s): Milk without fortification
D: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a 60 week study including a double-blind phase followed by an open-label extension phase.


Options:
A: Intervention Type: DRUG; Name: Botulinum toxin A injection or normal saline; Assigned to Arm(s): N/A
B: Arm Label: botulinum toxin Type A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo (saline) | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): botulinum toxin Type A | Intervention Type: OTHER; Name: placebo (saline); Assigned to Arm(s): Placebo (saline)
C: Intervention Type: DRUG; Name: Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection; Assigned to Arm(s): N/A
D: Arm Label: botulinum toxin Type A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): botulinum toxin Type A | Intervention Type: OTHER; Name: Placebo (saline); Assigned to Arm(s): Placebo (saline)

Answer: D